Cancer Therapy

Lpath creates neutralizing monoclonal antibodies against LPA, a cancer target

Published in Cancer Weekly, August 15th, 2006

Lpath, Inc., (LPTN) reported it is the first to generate functional antibodies against lysophosphatidic acid (LPA), a key bioactive lipid and a potent cancer promoter.

The cancer-research community has long recognized LPA as a significant contributor to cancer through its promotion of cancer-cell growth and metastasis in a broad range of tumor types. In response, many academics, biotechs, and pharmaceutical companies have all tried - without success - to produce drugs, including antibodies, that target LPA and neutralize its potent tumorigenic effects.

Using its proprietary ImmuneY2 technology, Lpath has not only succeeded in generating monoclonal...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2006-08-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry